Primary antibody deficiencies (PADs) are the most frequent primary immunodeficiencies in human subjects. 1 PADs are a group of diseases generally characterized by impaired B-cell differentiation and function, which results in low immunoglobulin production. They have a spectrum of underlying causes and phenotypic expressivity. 2 Differentiation of B lymphocytes into plasma cells (PCs) requires extensive morphologic and homeostatic changes, 3 such as expansion of the endoplasmic reticulum (ER), which allows PCs to become secretory factories releasing thousands of antibodies per second. 4 This massive immunoglobulin production is accompanied by accumulation of misfolded proteins in the ER, which activates the unfolded protein response (UPR). The UPR must be constitutively maintained in PCs to cope with perpetual ER stress to ensure longevity. 5 Of the existing signaling pathways regulating the UPR in mammals (inositol-requiring enzyme 1a
[IRE1A]/spliced X-box binding protein 1 [XBP1s], PKR-like ER kinase [PERK]/activating transcription factor [ATF] 4, and ATF6/ATF6f), only the IRE1A/XBP1s pathway is required for differentiation of B cells into PCs. 6, 7 After sensing ER stress, IRE1A is activated by phosphorylation. Active IRE1A triggers splicing of the ''unspliced'' transcriptional activator XBP1u through excision of a 23-bp intron from its mRNA, resulting in XBP1s. 8, 9 XBP1s increases the synthetic capacities of cells by inducing the transcription of genes encoding mediators of protein synthesis, transport, folding, and degradation. 10 However, which of the many target genes of XBP1s are critical for PC differentiation is poorly understood.
Interestingly, the PERK/ATF4 pathway of the UPR is specifically suppressed during differentiation of B cells into PCs. 6 PERK activation leads to global downregulation of protein synthesis and concomitantly increased levels of ATF4, which induces the transcription of C/EBP homologous protein (CHOP). CHOP is a mediator of the terminal UPR that induces apoptosis in situations of unresolvable ER stress. 11 Therefore activation of the PERK/ATF4 pathway would be incompatible with development of a long-lived humoral immune response.
Genes encoding the Sec61 complex are targets of the UPR. 10 This protein complex cotranslationally or posttranslationally transports nascent polypeptides from the cytosol into the ER lumen or inserts them into the ER membrane. 12 The heterotrimeric Sec61 complex is composed of large Sec61 translocon alpha 1 (SEC61A1) subunit and the much smaller SEC61B and SEC61G subunits. 13 In its open state the Sec61 channel forms a large aqueous pore in the ER membrane that is penetrable for small molecules and ions.
14 Indeed, the Sec61 complex acts as a passive calcium (Ca 21 ) leakage channel. 15 Therefore, SEC61A1 contains a highly conserved domain called the ''pore ring'' that tightly surrounds the nascent polypeptide to limit Ca 21 leakage through the opened channel. 13 Here we describe 2 families with early-onset, severe, recurrent bacterial infections of the respiratory tract with antibody isotype deficiencies involving IgM, IgG, and IgA. By using whole-exome sequencing in the first family and targeted sequencing in the second family, we identified a heterozygous missense mutation and a heterozygous nonsense mutation in SEC61A1. The missense mutation is located within the pore ring of SEC61A1. Affected subjects had normal numbers and subsets of peripheral B cells, but these did not differentiate into PCs in vitro. We show that SEC61A1-V85D overexpression boosts ER stress because of an increased Ca 21 leakage and impaired protein translocation in HeLa cells and activates the terminal UPR in multiple myeloma (MM) cell lines.
METHODS

Ethics approval
All subjects donated samples after informed written consent under local ethics board-approved protocols: 295/13_140782 from August 19 2014 (''Klinik und molekulargenetischer Defekt des variablen Immundefekts [CVID]''; ethics committee of the Albert-Ludwigs-University Freiburg).
B-cell stimulation assay
B cells were isolated from PBMCs with the B-cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Thirty thousand CD19
1 B cells (purity >90%, mostly >99%) were seeded in triplicates for each time point and stimulated in 200 mL of medium (Iscove modified Dulbecco medium supplemented with 10% FBS, 1% penicillin/streptomycin, 2.5 mg/mL transferrin, 1 mg/mL glutathione, 1 mg/mL insulin, 2 mmol/L L-glutamine, 13 nonessential amino acids, and 0.1% fatty acid supplement) containing 2 mg/mL anti-IgM antibody (#2020-10; SouthernBiotech, Birmingham, Ala), 0.5 mmol/L CpG (#153100; Apara Bioscience, Baden-W€ urttemberg, Germany), and 0.1 mg/mL Baff-3mer or CD40 ligand (CD40L) and IL-21 (Baff-3mer, CD40L, and IL-21 were produced, titrated, and kindly provided by the laboratory of Professor Eibel) in a 96-well round-bottom culture plate for 9 days. The medium was changed (100 mL of medium was replaced by fresh, 2-fold concentrated stimulation medium) every 3 days.
SEC61A1 silencing and expression
To rescue the phenotype of SEC61A1 silencing and functionally characterize the SEC61A1-V85D mutant, the respective cDNAs of the wild-type (WT) or mutant were inserted into the multicloning sites of the pCMV6-AC-IRES-GFP-vector (OriGene, Rockville, Md). For gene silencing, 6 3 10 5 HeLa cells were seeded per 6-cm culture plate. The cells were transfected with SEC61A1-UTR (CACUGAAAUGUCUACGUUUtt) small interfering RNA (siRNA; Qiagen, Hilden, Germany) or control siRNA (AllStars Negative Control siRNA; Qiagen) by using HiPerFect Reagent (Qiagen) for 96 hours, as described previously (final concentration of siRNAs, 20 nmol/L). 16 siRNA transfection was repeated after 24 hours. Six hours after the first siRNA transfection, the cells were transfected with pCMV6 expression plasmids with Fugene HD (Promega, Fitchburg, Wis).
Preprolactin processing and cytochrome B5 glycosylation
Two established model precursor polypeptides were used for quantitative analysis of both SEC61-dependent (bovine preprolactin [ppl] ) and SEC61-independent (tail-anchored hybrid protein Cytb5-ops28) protein transport into the ER of semipermeabilized HeLa cells in vitro. 
Live cell calcium imaging
HeLa cells were transfected with FuGene HD (Promega) 8 hours after seeding with SEC61A1 expression plasmids in combination with a SEC61B-IRES-SEC61G encoding pCDNA3-IRES-GFP expression plasmid. Live cell calcium imaging for cytosolic Ca 21 was carried out, as described previously. 20 
Viral transduction of cell lines
The respective cDNAs of WT or mutant SEC61A1 were inserted into the multicloning sites of the pMXS-IRES-GFP retroviral expression vector. HEK293T cells were transiently transfected with X-tremeGene HP DNATransfection Reagent (Roche, Basel, Switzerland) with 5 mg of expression plasmid and 5 mg of pCL-ampho retrovirus packaging vector (Imgenex, San Diego, Calif). Medium was changed after 24 hours, and virus was harvested 48 and 72 hours after transfection. Cell lines were treated on 2 consecutive days with virus-containing medium and fresh medium in a 1:1 ratio. Spin infection was carried out for 2 to 3 hours at 870g. Infection efficiencies were analyzed by using flow cytometry. Fluorescence-activated cell sorting was carried out with a MoFlo Astrios Cell Sorter (Beckman Coulter, Fullerton, Calif). MM cells were sorted 1 day after the second viral transduction. Transduced HEK293T cells were expanded in culture for 1 week before sorting. Additional Methods can be found in this article's Online Repository at www.jacionline.org.
RESULTS
Clinical description of the families
We investigated 10 subjects in family I (Fig 1, A) who had antibody isotype deficiencies involving IgM, IgG, and IgA (see Table E1 in this article's Online Repository at www.jacionline. org) and severe recurrent bacterial infections, such as tonsillitis, otitis, sinusitis, pneumonias, and gastrointestinal infections. Disease onset was mostly in the first year of life. Affected subjects did not respond to polysaccharide vaccination and responded variably to tetanus toxin vaccination (see Table E1 ). They have successfully maintained a marked decrease in the number and severity of infections since initiating immunoglobulin replacement therapy with intravenous immunoglobulin (IVIG; detailed case reports can be found in this article's Online Repository at www.jacionline.org).
The index patient of family II (Fig 1, A) was an 8-year-old boy with hypogammaglobulinemia since birth but who, because of IVIG treatment, has not experienced any severe or recurrent infections (II.P3; a detailed case report is provided in this article's Online Repository). Attempts to withdraw IVIG treatment repeatedly failed because of persistently low immunoglobulin serum levels (see Table E1 ). His mother (who is affected by a secondary immunodeficiency and therefore not included in this study) and grandmother (II.P1) are also mutation carriers; the latter reported an increased frequency of upper respiratory tract infections during childhood with recurrent bilateral bacterial otitis media. Now, at age 66 years, she has normal immunoglobulin serum levels (see Table E1 ).
Identification of heterozygous mutations in SEC61A1
We performed linkage analysis using microsatellite markers to identify the genetic region harboring the disease-causing mutation in family I. A genome-wide scan of all autosomes revealed only 1 region, on chromosome 3, with logarithm of the odds (LOD) scores of greater than 2. The high scores were achieved at consecutive markers. Fine mapping confirmed genetic linkage to chromosome 3. The peak single-marker and multiple-marker LOD score was 3.31. Genetic linkage analysis established that the mutated gene should be between markers D3S3697 and D3S3684 (see Table E2 in this article's Online Repository at www.jacionline.org).
Next, we performed whole-exome sequencing on 6 members of family I (I.P7, P8, P9, P10, H1, and H2). Evaluation of all variants shared among the 4 affected subjects and absent in the 2 unaffected family members revealed 3 novel single nucleotide variants in the genes SEC61A1, GOLGA8K, and SLC47A2, with only SEC61A1 located in the linkage region on chromosome 3 (see Table E3 in this article's Online Repository at www.jacionline.org). Using Sanger sequencing, we confirmed that the heterozygous missense mutation (c.254T>A, p.V85D) in SEC61A1 perfectly segregated with the disease within family I (Fig 1, B) . c.254T>A in SEC61A1 translates into a p.Val85Asp change (p.V85D), predicted as ''damaging'' by using the programs SIFT 21 (score 5 0.000), Provean 22 (score 5 26.26), and MutationTaster 23 (score 5 4.15). The V85 residue of SEC61A1 (Fig 1, C , in magenta) is one of 6 bulky and hydrophobic amino acids that form the pore ring in the middle of the Sec61 channel (blue and magenta side chains in Fig 1,  C) . Furthermore, V85 is highly conserved (Fig 1, D) , and a valine to aspartic acid change substitutes a hydrophobic and neutral amino acid for a hydrophilic and negatively charged residue, which is predicted to alter the structure, functional properties, or both of the Sec61 channel.
Seeking additional subjects with SEC61A1 mutations, we performed targeted next-generation sequencing in more than 200 additional patients with PADs. We identified a heterozygous nonsense mutation (c.1325G>T, p.E381*) in subject II.P3 from family II. Using Sanger resequencing, we confirmed this mutation and identified 2 additional mutation carriers in the family (Fig 1,  B) . In the genome aggregation database (gnomAD), which includes data from 123,136 exomes (ExAc data) and an additional 15,496 genomes, there are no mutations reported in healthy subjects, leading to a premature stop codon in SEC61A1. Moreover, SEC61A1 was a promising candidate because it is a target gene of XBP1s during PC differentiation. [24] [25] [26] As determined by using mass spectrometry-based proteomics, 27 the relative abundance of SEC61A protein is 2-fold higher in plasmablasts from human peripheral blood when compared with that in naive and memory B cells (Fig 1, E) . 27 The p.E381* nonsense mutation in family II leads to SEC61A1 haploinsufficiency
Nonsense mutations lead to a premature stop of translation, resulting in either synthesis of a shortened protein or nonsense-mediated mRNA decay. We analyzed SEC61A1 protein levels in sorted naive B cells (CD19 1 CD27
2 ) and CD3 1 CD4
2
T cells of subjects II.P1 and II.P3. We observed reduced levels of SEC61A1 in naive B cells of subjects II.P1 and II.P3, whereas SEC61A1 levels in CD8 1 T cells were comparable with control values (Fig 1, F) . Using a second antibody recognizing the N-terminal domain of SEC61A1 in lysates from an EBV-transformed B-cell line of II.P3, we excluded the presence Mutations in SEC61A1 in patients with hypogammaglobulinemia. A, Pedigrees of 2 families with germline SEC61A1 mutations. Squares, Male subjects; circles, female subjects; black symbols, mutation carriers; asterisks, genetically tested. B, Confirmation of mutations by using Sanger sequencing, showing the heterozygous changes in the coding sequence (c) and the protein sequence (p). mut, Mutant. C, Atomic model of the heterotrimeric Sec61 complex in the laterally closed conformation seen from cytoplasm composed of SEC61A1 (blue), SEC61B (orange), and SEC61G (yellow). Pore ring residues in the center of the channel are shown in blue, with the mutated V85 in magenta. The plug domain (transparent) reaches into the pore from the back. D, Protein sequence alignment of SEC61A1 from various species, including vertebrates and fungi. Mutated V85 is highlighted in magenta. E, Log 2 of label-free quantitation (LFQ) values of SEC61A1, as determined by means of mass spectrometry-based proteomics in human cells sorted from peripheral blood. Data were taken from Rieckmann et al. 27 mB, Memory B cells; nB, naive B cells; PB, plasmablasts. F, Western blot analysis of SEC61A1 levels in sorted primary CD19 Affected subjects in both families have normal peripheral B-and T-cell subpopulations
Circulating B-and T-cell populations of patients from both families were analyzed by using flow cytometry. B, T, and natural killer cells were present at normal ratios (Fig 2, A , and see Table  E4 in this article's Online Repository at www.jacionline.org), and the patients did not show any abnormalities in detailed T-cell phenotyping when looking at naive, memory, and effector T-cell stages in CD8
1 and CD4 1 T cells. They also had normal numbers of regulatory T cells and recent thymic emigrants (see Table E4 )
low B cells were also normal (Fig 2, B, all lymphocyte values are displayed in Table E4 ). Only the very small population of peripheral CD27
1
CD38
high plasmablasts appeared to be reduced in patients of family I (Fig 2, B) . However, because this is a very small cell population, which can be lower than 1% of B cells in healthy subjects, but increase dramatically during infection; this value is rather error prone.
B cells of mutation carriers have an intrinsic deficiency to develop into PCs
The initial observations on B cells prompted us to study PC development. To assess whether the B cells of patients have an intrinsic differentiation defect, we stimulated purified B cells for 9 days, mimicking T cell-dependent (CD40L and IL-21) and T cell-independent (anti-IgM, B cell-activating factor of the TNF family [BAFF], and CpG) activation. The differentiation of resting peripheral B cells into CD27 1 CD38 high plasmablasts and CD38 high CD138
1 PCs was significantly decreased in mutation carriers from both families on T cell-dependent (Fig 3, A and B) and T cell-independent (see Fig E2, A and B, in this article's Online Repository at www.jacionline.org) stimulation. Furthermore, on CD40L/IL-21 stimulation, B cells from affected subjects had decreased IgG and IgA production but no significantly different IgM production (Fig 3, C) . Similarly, IgG and IgA levels were significantly lower for cells from affected subjects on polyclonal stimulation with CpG, BAFF, and anti-IgM (see Fig E2, C) , whereas IgM was not secreted by the cells after this stimulation.
EBV-transformed B-cell lines carrying SEC61A1 mutations secrete less immunoglobulin
To substantiate the results of the primary B-cell stimulation assay, we studied EBV-transformed B-cell lines of several subjects of families I and II. First, we analyzed protein and mRNA levels in 4 healthy donor cell lines, 3 cell lines generated from family I, and 1 cell line from subject II.P3. We observed significantly reduced protein and mRNA levels in all cell lines from patients (Fig 4, A and B) , with the cell line of subjects II.P3 having the lowest mRNA expression levels (triangle in Fig 4, B) .
If the reduced protein levels were a product of decreased stability of the p.V85D mutant protein, we would have expected similar or even increased mRNA levels in family I compared with the control subjects. Because mRNA and protein levels were both reduced and EBV cell lines are known to have a high phenotypic variability, we stained 5 control subject and 4 patient EBV cell lines for B-cell surface markers. Intriguingly, we observed that all healthy donor cell lines contained a subpopulation of CD38 high CD138 1 PCs that was absent in all patient-derived cell lines (Fig 4, C) . This result prompted us to analyze immunoglobulin secretion levels of the cells by using ELISpot. The mean spot size, representing the secretion capacity per cell, was significantly reduced in cells from the patients compared with control subjects for IgG, IgA, and IgM (Fig 4, D) . Taken together, these data provide a link between low SEC61A1 expression levels and reduced immunoglobulin secretion by B lymphoblasts.
Protein translocation by the SEC61A1-V85D channel is impaired
The main function of SEC61A1, as the central subunit of the Sec61 channel, is the transport of nascent polypeptides into the ER. To test whether cotranslational protein transport was still functional in mutated translocons, we silenced the endogenous SEC61A1 mRNA in HeLa cells followed by complementation with either the WTor mutant SEC61A1 protein, by using their respective expression plasmids (Fig 5, A) . Transport of ppl through the Sec61 complex was assessed in semipermeabilized cells. Ppl is an established model precursor polypeptide for studying the general effects of SEC61A1 missense mutations on Sec61-dependent cotranslational protein translocation. On transport into the ER, the signal peptide of the ppl is cleaved by a signal peptidase, leaving the mature prolactin protein. We observed that cotranslational transport of ppl through the SEC61A1-V85D channel was significantly decreased compared with transport through the WT channel (Fig 5, B) . In contrast, SEC61A1-independent membrane insertion of the tail-anchored protein cytochrome B5 and concomitant N-glycosylation were not impaired (Fig 5, C) , reflecting the integrity of the ER membrane in SEC61A1-V85D-producing cells.
Dissipation of the ER/cytosol calcium gradient in SEC61A1-V85D-producing HeLa cells
Localization of the p.V85D mutation in the pore ring of SEC61A1 suggested that the ion permeability of the ER membrane, especially concerning maintenance of the calcium gradient between ER lumen and cytosol, might play a role in disease pathogenesis. To investigate the influence of the p.V85D mutation on the leakiness of the SEC61A1 channel for Ca 21 ions, we transiently overproduced SEC61A1-V85D together with its interaction partners, SEC61B and SEC61G, in HeLa cells (Fig 6, A) . The cells were then loaded with the calcium indicator Fura2 and treated with thapsigargin, an inhibitor of the SERCA-ATPase, to visualize leakage of calcium from the ER into the cytosol by means of live cell imaging. Overproduction of the WT protein resulted in increased leakage (Fig 6, B) in accordance with its role as a calcium leak channel.
Unexpectedly, we observed a significant decrease in calcium leakage in cells overproducing SEC61A1-V85D compared with cells with endogenous SEC61A1 protein levels or cells overproducing SEC61A1-WT (Fig 6, B) . This could be explained either by a decreased leakiness of the SEC61A1-V85D channel or, on the contrary, by a severe increase of its leakiness, resulting in a depletion of the ER/cytosol Ca 21 gradient. Indeed, treating the cells with ionomycin to assess the total amount of calcium ions in the ER lumen revealed that the calcium load of the ER was significantly decreased in cells overproducing the mutant channel in comparison with cells overproducing the WT form (Fig 6, C) , thus supporting the latter hypothesis. Because these experiments were carried out in cells overexpressing SEC61A1-V85D without prior silencing of endogenous SEC61A1, we conclude that the effect on the ER/cytosol Ca 21 gradient is a dominant effect of SEC61A1-V85D.
SEC61A1-V85D production selectively affects PCs
To study the effect of stable expression of SEC61A1-V85D on PCs, we used 3 different MM cell lines: JK6L, U266, and L-363. Whereas JK6L cells still secrete high amounts of IgG, U266 and L-363 cells do not secrete antibodies (see Fig E3 in this article' s Online Repository at www.jacionline.org); nevertheless, they still Data are represented as means 6 SDs. *P < .05 and **P < .005. ns, Not significant (unpaired t test).
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 4 have the morphology of PCs. 28 Stable transduction with a vector encoding SEC61A1-V85D-IRES-GFP resulted in the disappearance of GFP 1 cells of all MM cell lines after several days in culture, whereas the expression of WT SEC61A1-IRES-GFP was stable (Fig 7, A , and see Fig E4 in this article' s Online Repository at www.jacionline.org). Interestingly, the IgG-secreting JK6L cells appeared to be more sensitive to SEC61A1-V85D protein than the non-immunoglobulinsecreting U266 and L-363 cells. Stable overexpression of WT and mutant SEC61A1 in other lymphocytic (EBV-transformed B cells and Jurkat T cells) and nonlymphocytic (THP-1 monocytes, HEK293T, HeLa, and HT29) cell lines did not affect the proliferation capacity or viability of those cells (Fig 7, A , and see Fig E4) . Taken together, these observations indicate that SEC61A1-V85D production selectively impairs the survival of PC lines. In line with the hypothesis, patients did not present additional clinical symptoms to infections, and laboratory values of proteins secreted by the liver and the pancreas into the serum were all within the normal ranges (see Table E5 in this article's Online Repository at www.jacionline.org).
SEC61A1-V85D production and SEC61A1 knockdown induces the terminal UPR in PC lines
Based on experiments in HeLa cells (Figs 5 and 6 ), we hypothesized that disturbed cellular calcium homeostasis, dysfunctional protein translocation, or both caused by SEC61A1-V85D might induce unresolvable ER stress and the terminal UPR in MM cells. To study this hypothesis, we analyzed MM cells overproducing SEC61A1-V85D by using Western blotting and RT-quantitative PCR. We observed significantly increased protein levels of the ER stress sensors IRE1A and PERK and their downstream transcription factors XBP1s and ATF4 in U266 cells (Fig 7, B) . Comparable results were obtained from the JK6L (see Fig E5, A, in this article's Online Repository at www.jacionline. org) and L-363 (see Fig E5, B) MM cell lines. Notably, the PERK/ATF4 pathway, which acts upstream of the apoptosisinducing transcription factor CHOP, seemed to be activated. By using RT-quantitative PCR analysis, we verified the activation of this pathway. In addition to XBP1s, mRNA levels of ATF4 and CHOP were upregulated on SEC61A1-V85D overexpression in L-363 cells (Fig 7, C) , pointing to activation of the terminal Data in bar graphs are represented as means 6 SDs. ns, Not significant. *P < .05, **P < .005, and ***P < .001 (unpaired t test). UPR in this PC line. To study the effect of SEC61A1 haploinsufficiency on PC homeostasis, we attempted to partially knockdown SEC61A1 in JK6L MM cell lines by using lentiviral vectors encoding 4 different shRNAs against SEC61A1. However, after puromycin selection, none of the 4 stably transduced cell lines had reduced SEC61A1 protein levels (data not shown), indicating that we had selected for clones that evaded shRNA knockdown while maintaining the puromycin resistance.
Next, we directly transfected the cells with siRNA against SEC61A1. In independent repeats optimizing the ratio of siRNA to transfection reagent and checking at different time points in JK6L, U266, and L363 cell lines, we found only once a reduction of SEC61A1 protein at 24 hours after transfection in JK6L cells. Intriguingly, those cells with a partial knockdown had increased expression levels of IRE1A and PERK, showing an increase of ER stress and induction of the UPR (Fig 7, E) . In summary, these results indicate that MM cells do not easily tolerate a knockdown of SEC61A1 and that knockdown might induce the UPR in JK6L cells.
Dominant effect of mutant SEC61A1-V85D in sensitized HEK293T cells
In accordance with the insensitivity of non-MM cell lines to the overexpression of SEC61A1-V85D (see Fig E4) , we did not observe induction of the terminal UPR in HEK293T or HT29 cells upon SEC61A1-V85D production (data not shown). This suggested that they were likely able to adapt to the effects of the mutant protein. To sensitize them toward overproduction of the mutant SEC61A1, we treated HEK293T cells stably overexpressing SEC61A1-V85D for 24 hours with thapsigargin to induce additional ER stress by mimicking a disturbance of the Ca 21 homeostasis. As expected, we observed a significantly higher induction of XBP1s in cells overproducing SEC61A1-V85D compared with cells overproducing the WT protein (Fig 7, D) . Interestingly, it made no difference whether the mutant was overexpressed alone or co-overexpressed with WT SEC61A1 (Fig 7, D) , thus showing a dominant effect of SEC61A1-V85D.
DISCUSSION
Currently known genetic causes for antibody deficiencies, some of which are diagnosed as common variable immunodeficiency (CVID), impair early B-cell development, B-cell receptor signaling, or the functionality of B or T cells in the germinal center reaction. 29 Even though CVID patients with only infections have been reported to present a considerable subset in CVID cohorts (eg, Resnick et al 30 : 32% of 473 subjects), hardly any of the known monogenic CVID disorders present with this clinical phenotype. 1, 29 To our knowledge, this is the first monogenic defect that specifically impairs PC homeostasis without interfering with B-cell development, activation, and memory formation.
We found 2 heterozygous SEC61A1 mutations in patients of 2 unrelated families with an early-onset, infection-only antibody deficiency and normal (sub-)populations of peripheral B cells. First, a missense mutation in the pore ring affected cotranslational protein transport and increased Ca 21 leakage from the ER, the latter representing a potential mechanism for a toxic dominant-negative effect of the mutant over the WT protein. Second, a nonsense mutation abrogated protein production from one of the 2 SEC61A1 alleles. It is known that SEC61A1 proteins with severe mutations compete poorly with WT proteins for binding of complex partners and are therefore degraded in a heterozygous situation. [31] [32] [33] In PCs concomitant increases in SEC61B and SEC61G levels might stabilize protein levels of previously degraded p.V85D mutants, resulting in dissipation of the ER/cytosol calcium gradient and increased ER stress. In addition, PCs, in contrast to most other cells, might require 2 functional SEC61A1 alleles to sufficiently induce SEC61A1 protein levels for excessive immunoglobulin production. We suggest that SEC61A1 haploinsufficiency is causing (possibly transient) hypogammaglobulinemia with variable expressivity or incomplete penetrance in family II. In contrast, a dominant negative mutation in SEC61A1 resulting in a functional haploinsufficiency in combination with a dominant negative disturbance of the calcium homeostasis might be responsible for the fully penetrant PADs in family I, ranging from transient hypogammaglobulinemia and specific antibody deficiency to CVID.
In human subjects Sec61 channelopathies have been linked, for example, to polycystic liver disease, diabetes, and congenital disorder of glycosylation caused by mutations in the transloconassociated proteins SEC63, ERJ6, and SSR4, respectively. [34] [35] [36] Moreover, in a mouse model a homozygous point mutation in Sec61a1 impaired binding of Sec61a1 to its interaction partner BiP and caused type 1 diabetes. 37 Evidence that variations in the SEC61 genes might be relevant to PC deficiency comes from a murine study, in which the conditional B cell-specific inactivation of Xbp1 resulted in reduced production of IgM and IgG and reduced expression levels of the Xbp1s target gene Sec61a1. 25 A recent study reported 2 heterozygous missense mutations in SEC61A1 in patients with autosomal dominant tubulointerstitial and glomerulocystic kidney disease (ADTKD) with anemia. 38 Laboratory values that were found to be altered in patients with ADTKD were normal in our patients (see Table  E6 in this article's Online Repository at www.jacionline.org). The effects of SEC61A1 missense mutations in patients with ADTKD on protein-protein interactions, intrinsic functionality, or protein stability were not investigated. However, heterozygous mutations that reduce the hydrophobicity of the signal peptide of renin cause ADTKD with a clinical phenotype similar to the phenotype associated with SEC61A1 mutations. These mutations interfere with SEC61 complex-dependent translocation of renin across the ER membrane and signal peptide cleavage, and hence the Sec61 complex is directly involved in disease pathogenesis. [39] [40] [41] Therefore it seems possible that the SEC61A1 mutations in patients with ADTKD specifically impair renin translocation and processing and therefore mirror the clinical phenotype of renin mutations.
In summary, we provide evidence that the disturbance of ER homeostasis interferes with PC functionality in human subjects and can cause PADs, as previously proposed by others. 42 We hypothesize that sensors, signaling components, and target genes of the UPR that play an important role in protein synthesis, modification, and secretion and in the maintenance of the ER homeostasis in PCs are likely to be mutated or dysregulated in other antibody-deficient patients with normal numbers of peripheral B cells.
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Key messages
d SEC61A1, a target gene of XBP1s during PC differentiation, was mutated in patients given a diagnosis of a PAD.
d The disease phenotype was limited to severe recurrent infections, mainly of the respiratory tract, and patients responded well to immunoglobulin replacement therapy.
d All patients had normal subpopulations of B and T cells in the peripheral blood, but in vitro PC homeostasis was impaired because of unresolvable ER stress.
